Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE | P22303 | 3/20 | 0.53 |
| ▸ | STAT3 | P40763 | 1/20 | 0.48 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.46 |
| ▸ | TRPA1 | O75762 | 3/20 | 0.43 |
| ▸ | GRIA4 | P48058 | 1/20 | 0.42 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.41 |
| ▸ | ESR1 | P03372 | 1/20 | 0.40 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.40 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.39 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20811781 | 1.00 | ACHE (0.53) | ACHESTAT3ABCB11TRPA1GRIA4 | |
| SCHEMBL12195408 | 1.00 | ACHE (0.53) | ACHESTAT3ABCB11TRPA1GRIA4 | |
| Alcohol SCHEMBL7608913 | 0.95 | ACHE (0.50) | ACHESTAT3ABCB11TRPA1GRIA4 | |
| SCHEMBL2641075 | 0.89 | ABCB11 (0.52) | ACHEABCB11TRPA1ESR1ESR2 | |
| SCHEMBL11041781 | 0.88 | GRIA4 (0.50) | ACHESTAT3ABCB11GRIA4GAA | |
| SCHEMBL10396706 | 0.82 | ABCB11 (0.47) | ABCB11TRPA1ESR1ESR2FFAR1 | |
| SCHEMBL9694221 | 0.82 | ABCB11 (0.47) | ABCB11TRPA1GRIA4ESR1ESR2 | |
| SCHEMBL6933308 | 0.82 | ABCB11 (0.47) | ACHESTAT3ABCB11TRPA1ESR1 | |
| SCHEMBL10396707 | 0.82 | ABCB11 (0.47) | ABCB11TRPA1ESR1ESR2FFAR1 | |
| SCHEMBL12746758 | 0.82 | ACHE (0.40) | ACHESTAT3ABCB11TRPA1GRIA4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-2096572-A | — | — | None | — | — | JP | disclosed |
| CN-118955244-A | Method for preparing primary alcohol by homogeneously catalyzing and reducing carboxylic acid derivative by using N-heterocyclic carbene copper complex | 延安大学 | 2024-11-15 | — | — | CN | disclosed |
| US-20240327764-A1 | Manufacturing a Distilled Spirit Based Functional Ingredient | BROCIA ROBERT (US) | 2024-10-03 | — | — | US | disclosed |
| CN-117794861-A | Process for producing pellets comprising magnesium ion containing material | OMYA国际股份公司 | 2024-03-29 | — | — | CN | disclosed |
| CN-113244117-B | Compositions providing delayed release of active substances | 诺赛尔股份有限公司 | 2023-10-20 | — | — | CN | disclosed |
| WO-2023191721-A2 | PRODUCTION OF ENANTIOPURE ALCOHOLS, AMINES AND ACIDS FROM ALKENES BY CASCADE BIOTRANSFORMATION INVOLVING 1,2-METHYL SHIFT | NATIONAL UNIVERSITY OF SINGAPORE (SG) | 2023-10-05 | — | — | WO | disclosed |
| US-20230019032-A1 | BENZOLACTAM COMPOUNDS AS PROTEIN KINASE INHIBITORS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2023-01-19 | — | — | US | disclosed |
| WO-2021160768-A1 | COMPOUNDS USEFUL AS ANTI-VIRAL AGENTS | NATURE CRETE PHARMACEUTICALS PC (GR) | 2021-08-19 | — | — | WO | disclosed |
| US-10457669-B2 | Benzolactam compounds as protein kinase inhibitors | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2019-10-29 | — | — | US | disclosed |
| US-20190047990-A1 | BENZOLACTAM COMPOUNDS AS PROTEIN KINASE INHIBITORS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2019-02-14 | — | — | US | disclosed |
| US-7300639-B2 | Process for removing metals from liquids | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-11-27 | — | — | US | disclosed |
| EP-0882715-B1 | NOVEL N-(UNSUBSTITUTED OR SUBSTITUTED)-4-SUBSTITUTED-6-(UNSUBSTITUTED OR SUBSTITUTED)PHENOXY-2-PYRIDINECARBOXAMIDES OR THIOCARBOXAMIDES, PROCESSES FOR PRODUCING THE SAME, AND HERBICIDES | KUREHA CHEMICAL IND CO LTD (JP) | 2003-04-23 | — | — | EP | disclosed |
| US-20030032806-A1 | Oxidation of carbon-boron bonds | CAI WEILING (US) | 2003-02-13 | — | — | US | disclosed |
| US-20020049352-A1 | Oxidation of carbon-boron bonds | CAI WEILING (US) | 2002-04-25 | — | — | US | disclosed |
| US-6339045-B1 | CAN BE USED IN A SMALL AMOUNT, SHOWING A GOOD SELECTIVITY BETWEEN CROP AND WEED, AND CAUSING NO PHYTOTOXICITY | KUREHA KAGAKU KOGYO KABUSHIKI KAISHA (JP) | 2002-01-15 | — | — | US | disclosed |
| EP-1167329-A2 | Oxidation of carbon-boron bonds | Pfizer Products Inc. (US) | 2002-01-02 | — | — | EP | disclosed |
| EP-0882715-A1 | NOVEL N-(UNSUBSTITUTED OR SUBSTITUTED)-4-SUBSTITUTED-6-(UNSUBSTITUTED OR SUBSTITUTED)PHENOXY-2-PYRIDINECARBOXAMIDES OR THIOCARBOXAMIDES, PROCESSES FOR PRODUCING THE SAME, AND HERBICIDES | KUREHA KAGAKU KOGYO KABUSHIKI KAISHA (JP) | 1998-12-09 | — | — | EP | disclosed |
| JP-H0296572-A | (-)-3-(P-TOLYL)GLYCIDOL | ADEKA ARGUS CHEM CO LTD | 1990-04-09 | — | — | JP | disclosed |
| US-4346242-A | Method for preparing substituted meta-phenylalkoxynitrobenzenes | AMERICAN CYANAMID COMPANY (US) | 1982-08-24 | — | — | US | disclosed |
| US-3968131-A | POLYOXYETHYLENE GLYCOL | BASF AKTIENGESELLSCHAFT (DT) | 1976-07-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230019032-A1 | BENZOLACTAM COMPOUNDS AS PROTEIN KINASE INHIBITORS | MAPK1, ALK, MAP3K1 | ACHE 4750/4885STAT3 384/4885ABCB11 2337/4885 |
| US-20030032806-A1 | Oxidation of carbon-boron bonds | CYBB, FOSB, SCO2 | ACHE 4086/4885STAT3 2373/4885ABCB11 1860/4885 |
| US-20190047990-A1 | BENZOLACTAM COMPOUNDS AS PROTEIN KINASE INHIBITORS | MAPK1, ALK, MAP3K1 | ACHE 4750/4885STAT3 384/4885ABCB11 2337/4885 |
| US-20020049352-A1 | Oxidation of carbon-boron bonds | CYBB, FOSB, SCO2 | ACHE 4086/4885STAT3 2373/4885ABCB11 1860/4885 |
| US-10457669-B2 | Benzolactam compounds as protein kinase inhibitors | MAPK1, ALK, MAP3K1 | ACHE 4750/4885STAT3 384/4885ABCB11 2337/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.